The increasing level of MMP7 over 1‐year post‐antifibrotic treatment may reflect underlying progression despite anti‐fibrotic treatment, with disease activity reduced in stable IPF. This evidence concerns the gene MMP7 and idiopathic pulmonary fibrosis.